Suppr超能文献

肿瘤坏死因子-α阻断成功治疗慢性复发性多灶性骨髓炎。

Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage.

作者信息

Deutschmann Andrea, Mache Christoph J, Bodo Koppany, Zebedin Doris, Ring Ekkehard

机构信息

Department of Pediatrics, Medical University of Graz, Graz, Austria.

出版信息

Pediatrics. 2005 Nov;116(5):1231-3. doi: 10.1542/peds.2004-2206.

Abstract

We describe the case of an 18-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) over a period of 10 years. She had suffered predominantly from very painful recurrent swelling of her cheeks. Various therapeutic regimens including nonsteroidal antiinflammatory drugs and steroids had shown only a partial or temporary response. Because tumor necrosis factor-alpha-blocking agents have been successfully applied in Crohn's-associated CRMO and the related SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, tumor necrosis factor-alpha-blocking therapy with infliximab was initiated. Thereafter, apart from 1 mild episode, no additional recurrences were observed during 21 months of follow-up. Infliximab was well tolerated, and steroids were tapered off. Our observation indicates that infliximab may be an effective therapeutic option in CRMO.

摘要

我们描述了一名18岁女孩患有慢性复发性多灶性骨髓炎(CRMO)长达10年的病例。她主要遭受脸颊反复出现的非常疼痛的肿胀。包括非甾体类抗炎药和类固醇在内的各种治疗方案仅显示出部分或暂时的反应。由于肿瘤坏死因子-α阻断剂已成功应用于克罗恩病相关的CRMO及相关的滑膜炎、痤疮、脓疱病、骨肥厚和骨炎(SAPHO)综合征,因此开始使用英夫利昔单抗进行肿瘤坏死因子-α阻断治疗。此后,除了1次轻度发作外,在21个月的随访期间未观察到额外的复发。英夫利昔单抗耐受性良好,类固醇药物逐渐减量。我们的观察表明,英夫利昔单抗可能是CRMO的一种有效治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验